2. Academic Validation
  3. Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy

Overcoming the Tumor Collagen Barriers: A Multistage Drug Delivery Strategy for DDR1-Mediated Resistant Colorectal Cancer Therapy

  • Adv Sci (Weinh). 2024 Jul 2:e2402107. doi: 10.1002/advs.202402107.
Guangman Cui 1,  Shaohui Deng 2,  Biao Zhang 1,  Manchun Wang 3,  Zhousheng Lin 4,  Xinyue Lan 3,  Zelong Li 4,  Guangyu Yao 4,  Meng Yu 3 5,  Jun Yan 1 6
Affiliations

Affiliations

  • 1 Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
  • 2 The Tenth Affiliated Hospital of Southern Medical University, Dongguan, Guangdong, 523059, China.
  • 3 NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • 4 Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
  • 5 Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
  • 6 Department of Gastrointestinal Surgery, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, 518020, China.
PMID: 38953306 DOI: 10.1002/advs.202402107
Abstract

The extracellular matrix (ECM) is critical for drug resistance in colorectal Cancer (CRC). The abundant collagen within the ECM significantly influences tumor progression and matrix-mediated drug resistance (MMDR) by binding to Discoidin Domain Receptor 1 (DDR1), but the specific mechanisms by which tumor cells modulate ECM via DDR1 and ultimately regulate TME remain poorly understand. Furthermore, overcoming drug resistance by modulating the tumor ECM remains a challenge in CRC treatment. In this study, a novel mechanism is elucidated by which DDR1 mediates the interactions between tumor cells and collagen, enhances collagen barriers, inhibits immune infiltration, promotes drug efflux, and leads to MMDR in CRC. To address this issue, a multistage Drug Delivery system carrying DDR1-siRNA and chemotherapeutic agents is employed to disrupt collagen barriers by silencing DDR1 in tumor, enhancing chemotherapy drugs diffusion and facilitating immune infiltration. These findings not only revealed a novel role for collagen-rich matrix mediated by DDR1 in tumor resistance, but also introduced a promising CRC treatment strategy.

Keywords

drug delivery; ecm modulation; multistage nanomedicine; sirna nanocarriers.

Figures
Products